Abstract Hepatocellular carcinoma (HCC) is highly malignant, and most patients are diagnosed at intermediate or advanced stages. Current regimens, including surgery, targeted therapy and immune checkpoint inhibitors (ICIs), are limited by low response rates, drug resistance, prominent toxicities and high costs, so safe...
Li-Yuan Hao, Li-Wei Li, Yi-Cheng Chen et al.· Drug Design, Development and...· 0 citations